-
Yes., always ask the patient. In an excellent study presented at
#ASCO18@EnriqueSoto8 found that Half of older patients with cancer rated other outcomes (particularly cognitive ability) as being more important than survival.#gerionc@myCARG@SIOGorghttps://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.10009 … -
During
#ASCO18 Annual Mtg, >17.5K Twitter users sent >80K tweets. Participate this Annual Mtg using#ASCO19. Use the standard#oncology hashtags in the pic & check out the@ASCO social media guide for tips! https://dailynews.ascopubs.org/do/10.1200/ADN.19.190183/full/?cid=DM1493&bid=9572151& …pic.twitter.com/Br6ehIrYi5
-
$NKTR$BMY peg-IL2 + PD1 combo in bladder cancer data abstract out for ASCO#GU19 https://meetinglibrary.asco.org/record/169673/abstract … ORR dropped to 48% (11/23) from 60% (6/10) at#ASCO18 -
Dr.
@NarjustDumaMD’s presentation on assoc btwn use of professional title & race/gender of introducer & speaker was excellent. Thousands of videos reviewed & coded from@ASCO#ASCO17 &#ASCO18 Annual mtgs. A labor of love, nicely done.#ASCO19 cc@HemOncWomenDocspic.twitter.com/IHQEPJnLge – mjesto: McCormick Place
-
EGFR exon 20 mutations: an urgent medical need. TAK-788 efficacy and safety. Small numbers but it’s way better than historic EGFR TKIs. ORR 43% PFS 7.9. Without brain mets: ORR 56% PFS 8.1. Most relevant toxicity: GI. Presented by
@RielyMD#ASCO18#LCSM@EGFRResisterspic.twitter.com/VYGmjBHPCV
-
This is special for sev reasons, above all b/c my grandma (& last grandparent) died hrs before I spoke at
#ASCO18. I showed her photo to end my talk. A bittersweet mtg. Now my grandpa is in#ASCO19 slides. Neither was in medicine. They would never believe it.
@IshwariaMDhttps://twitter.com/stage4kelly/status/1134585668926132224 …
-
No role for adjuvant VEGFR TKI following metastasectomy in mRCC by L Appleman
#ASCO19 confirming RESORT#ASCO18 - waiting for IO in this space! pic.twitter.com/LvSk72ADEa
-
Yes - good PS + continued afebrile status, good PO intake, excellent family support and home-to-hospital proximity were all key factors in this “record” run - everything has to go right for this to even be considered.
@MoffittNews had an#ASCO18 abstract https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e19013 … -
Flashback to #ASCO18 when@DanPollyea spoke on the promising therapies, both approved and coming through, in#AML. We are interested
in the acute myeloid leukemia advances being discussed during #ASCO19, are you?#leusm#leukemia@ASCOpic.twitter.com/KKEUb8mGjWPromising therapies in acute myeloid leukemia #ASCO18At the ASCO 2018 Annual Meeting, Daniel Pollyea from University of Colorado School of Medicine, Denver, US, talks about BCL-2 inhibition in AML. -
Reportable actionability versus pragmatic actionability: Implementing
#PrecisionMedicine at three large health systems.@mtmdphd et al.@Aurora_Cancer@HenryFordNews@hoaghealth@Syapse Abstract 6539#ASCO18 http://ow.ly/6E0A30m7xj6 pic.twitter.com/HPdTSseCWF
-
Successful automated normalization of cancer outcomes for half a million patients across four disparate health systems. Tittel et al.
@Syapse#ASCO18 Abstract e18763 http://ow.ly/QZsC30m7xdR#PrecisionMedicine -
Mind blowing that this happens in 2017-2018
Excellent job by @NarjustDumaMD@MKnoll_MD@ShikhaJainMD et al highlighting#unconsciousbias in speaker introductions at#ASCO17 &#ASCO18 Should address ALL physicians as Dr. Link: https://ascopubs.org/doi/full/10.1200/JCO.19.01608 …#OncoAlertpic.twitter.com/Q2SWHXfpgp
-
Congratulations to our
#Korean colleagues for publishing in@JCO_ASCO the results of the#ASTRRA trial presented at#ASCO18: more evidence on the role of adding#OvarianSuppression to#tamoxifen in premenopausal#BreastCancer patients#OncoAlert#bcsmhttps://ascopubs.org/doi/pdf/10.1200/JCO.19.00126#.XX6cC8GW1jc.twitter … -
Osi showed activity in rare muts. There was a presentation about a phase II at
#asco18 with 36 pts with ORR 50% but PFS 9.5 months. I personally would consider chemo +gef. In@VanitaNoronha’s study 60 pts x arm with Exon 21 mut and experimental arm did a lot better.#oncoalert -
I never lost an opportunity to have a selfie with the superstar
@EnriqueSoto8 (this picture below is from#asco18 Unfortunately I’m not going to#MASCC19 to have a new selfie - but certainly will be following on@Twitter :-)pic.twitter.com/O1ZENDw2Rw
-
A5. Results presented at
#ASCO18 showed great response to mFOLFIRINOX in#pancreaticcancer pts after surgery (http://pcan.at/pit592 );@ASCO guidelines were recently updated to include this recommendation.#PancChat -
Thank you very much, very kind to share the slide! Hope these data are helpful for our young
#BreastCancer patients...and looking forward to seeing the publication of the important study by Dr. Poorvu (@YoungStrongDFCI group) presented at#ASCO18 -
-
The
#PERSEPHONE trial presented at#ASCO18 just published in@TheLancet: shorter duration of#trastuzumab can be considered an option for selected patients with#HER2-positive early#BreastCancer#bcsmhttps://twitter.com/TheLancet/status/1136763445582471169 …
-
Duma et al (Abstr 10503) Just stunning - Female speakers @
#ASCO17 &#ASCO18 were 6x more likely to be introduced only by 1st name, not professional title, than males. And black speakers rec'd proper professional address 31% vs. 73% for whites https://meetinglibrary.asco.org/record/173397/abstract …#ASCO19pic.twitter.com/qYmGhIKBGD
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.